Funding
Funding was provided by ANGLE plc. The project described was supported in part by award number P30CA014089 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Debasish Tripathy has received research support (paid to the institution) from Novartis, Pfizer, and Polyphor, and consulting fees (paid to self) from AstraZeneca, GlaxoSmithKline, Gilead, Exact Sciences, OncoPep, Novartis, and Pfizer. Irene Kang has received speaker’s bureau fees and consulting fees from Puma Biotechnology, and consulting fees from Bristol Myers Squibb. Michael Press has undertaken a consulting or advisory role for AstraZenecca, Biocartis, Cepheid, Inc., Eli Lilly & Company, Merck & Co., and Puma Biotechnology; has provided expert testimony for Amgen, Inc.; and has private equity interests in TORL Biotherapeutics, LLC.
Competing interests
The authors declare no competing interests for the presented study. Although ANGLE plc provided research funds to the author’s institution, the authors have no relevant financial disclosures. The study sponsor did not influence data acquisition, analysis, or the decision to publish.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ring, A., Campo, D., Porras, T.B. et al. ASO Visual Abstract: Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer. Ann Surg Oncol 29, 2897–2898 (2022). https://doi.org/10.1245/s10434-021-11216-2
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-021-11216-2